[go: up one dir, main page]

EP2430012B1 - 7-aza-spiro[3,5]nonan-7-carboxylatderivate, deren herstellung und deren therapeutische verwendung - Google Patents

7-aza-spiro[3,5]nonan-7-carboxylatderivate, deren herstellung und deren therapeutische verwendung Download PDF

Info

Publication number
EP2430012B1
EP2430012B1 EP10728742.7A EP10728742A EP2430012B1 EP 2430012 B1 EP2430012 B1 EP 2430012B1 EP 10728742 A EP10728742 A EP 10728742A EP 2430012 B1 EP2430012 B1 EP 2430012B1
Authority
EP
European Patent Office
Prior art keywords
aza
spiro
carboxylate
ylmethyl
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10728742.7A
Other languages
English (en)
French (fr)
Other versions
EP2430012A1 (de
Inventor
Ahmed Abouabdellah
Nathalie Chereze
Aude Fayol
Alistair Lochead
Mourad Saady
Julien Vache
Philippe Yaiche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of EP2430012A1 publication Critical patent/EP2430012A1/de
Application granted granted Critical
Publication of EP2430012B1 publication Critical patent/EP2430012B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the subject of the invention is 7-azaspiro [3.5] nonane-7-carboxylate derivatives, their preparation and their therapeutic application. There is still a need to find and develop products that inhibit the enzyme FAAH (Fatty Acid Amide Hydrolase).
  • the compounds of the invention fulfill this purpose.
  • a first subgroup of compounds is composed of compounds for which R 2 represents a hydrogen atom.
  • a second subgroup of compounds is composed of compounds for which m, n, o and p have the value of 1, or, p and o have the value 1, n and m have for value 2, or n, o and p have the value 1 and ma for value 2.
  • an eighth subgroup of compounds consists of compounds for which R 3 represents a hydrogen atom.
  • a ninth subgroup of compounds is composed of compounds for which R 4 represents a thiazol-4-yl group; this group being unsubstituted.
  • a tenth subgroup of compounds is composed of compounds for which R 4 represents a thiazol-2-yl group; this group being substituted by one or more groups CONR 8 R 9 ; R 8 and R 9 independently of one another represent a hydrogen atom or a C 1-6 -alkyl group. More particularly, the C 1-6 alkyl group is methyl.
  • an eleventh subgroup of compounds is composed of compounds for which R 4 represents an isoxazol-5-yl group; this group being substituted by one or more groups CONR 8 R 9 ; R 8 and R 9 independently of one another represent a hydrogen atom or a C 1-6 -alkyl group. More particularly, the C 1-6 alkyl group is methyl.
  • a twelfth subgroup of compounds is composed of compounds for which R 4 represents a group chosen from a 1H-1,2,4-triazol-5-yl; this group being substituted by one or more C 1-6 -alkyl groups.
  • a thirteenth subgroup of compounds is composed of compounds for which R 4 represents a group chosen from an oxazol-2-yl; this group being substituted by one or more groups CONR 8 R 9 ; R 8 and R 9 independently of one another represent a hydrogen atom or a C 1-6 -alkyl group. More particularly, the C 1-6 alkyl group is methyl.
  • a fourteenth subgroup of compounds is constituted by the compounds of general formula (I) in which both R 1 and / or R 2 and / or R 3 and / or R 4 and / or n and / or m and / or o and / or p and / or A are as defined in the groups above.
  • the compounds of general formula (I) may comprise one or more asymmetric carbons. They can exist as enantiomers or diastereoisomers.
  • the compounds of general formula (I) may also exist in the form of cis or trans stereoisomers . These stereoisomers, enantiomers and diastereoisomers, as well as their mixtures, including racemic mixtures, form part of the invention.
  • the compounds of formula (I) may exist in the form of bases or addition salts with acids. Such addition salts are part of the invention.
  • salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) are also part of the invention.
  • the compounds of the invention can be prepared according to various methods, illustrated by the following diagrams. These methods, as well as the intermediate compounds used, are an object of the present invention.
  • a first preparation method (scheme 1) consists of reacting an amine of general formula (II), in which A, R 1 , R 2 , m, n, o and p are as defined in the general formula (I ) defined above, with a carbonate of general formula (III) in which Z represents a hydrogen atom or a nitro group, R 3 and R 4 are as defined in the general formula (I) defined above, in the presence of a base such as triethylamine, pyridine, N, N- dimethylaminopyridine or N, N -diisopropylethylamine, in a solvent such as toluene, acetonitrile or dichloroethane, at a temperature between the temperature ambient and the reflux temperature of the solvent.
  • a base such as triethylamine, pyridine, N, N- dimethylaminopyridine or N, N -diisopropylethylamine
  • the carbamate derivative (Ia) thus obtained is then converted into a compound of general formula (I) by the action of an alcohol of general formula R 1 OH (IV) as defined above, using the reaction conditions of Mitsunobu or by action of a halogenated derivative of the general formula R 1 X (IVa) as defined above using aromatic nucleophilic, heteroaromatic or O-arylation, O-heteroarylation substitution reactions of Buchwald, for example by means of a palladium or copper catalyst.
  • Another subject of the present invention relates to the compounds of formula (III) in which Z represents a hydrogen atom or a nitro group, R 3 is as defined in formula (I) and R 4 represents a 4- (methylcarbamoyl) -oxazol-2-yl group.
  • Another subject of the present invention relates to compounds of general formula (Ib) in which A, R 2 , R 3 , R 4 , R 5 , m, n, o and p are as defined in the general formula (I) according to claim 1 and U 1 represents a chlorine or bromine atom, of iodine or a triflate group.
  • Compound No. 9 is a mixture of isomers.
  • Compound No. 10 is the isomer I of compound No. 9 and compound No. 11 is the isomer II of compound No. 9.
  • Compound No. 29 is a mixture of isomers.
  • Compound No. 32 is the isomer I of compound No. 29 and compound No. 33 is isomer II of compound No. 29.
  • Compounds 14, 15, 26, 27, 28, 30 and 31 are mixtures of isomers.
  • the organic phase is washed twice with a 1N aqueous sodium hydroxide solution and then three times with saturated aqueous ammonium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness. 0.33 g of the expected product is obtained in the form of a powder, used as it is in the next step.
  • thiazol-4-ylmethyl 2-acetoxy-7-aza-spiro [3.5] nonane-7-carboxylate obtained in step 1.2.
  • Is dissolved in 2 ml of methanol and then 0 5 mL of water and 0.114 g (0.82 mmol) of potassium carbonate are added. After stirring for 1 hour at room temperature, the medium is concentrated in vacuo and then taken up with water. The aqueous solution is extracted twice with dichloromethane and the organic phases are combined, dried over sodium sulfate, filtered and concentrated to dryness. 0.222 g of the expected product is obtained in the form of a colorless oil.
  • the residue obtained is taken up in water and extracted twice with ethyl acetate. The combined organic phases are dried over sodium sulfate, filtered and concentrated in vacuo. The residue obtained is purified by chromatography on silica gel, eluting with a 50/50 to 80/20 mixture of cyclohexane and ethyl acetate. 0.04 g of expected product is obtained in the form of a solid.
  • the medium at room temperature is concentrated in vacuo and the residue obtained is chromatographed on preparative silica gel plates, eluting with a 95/5 / 0.5 mixture of dichloromethane, methanol and 30% aqueous ammonia. 0.073 g of the expected product is thus obtained in the form of a white powder.
  • 2,347 g (10.24 mmol) of 2-acetoxymethyl-thiazole-4-carboxylate of ethyl, obtained in step 5.2.1, are solution in 100 mL of a 5/1 mixture of dichloromethane and methanol. 2.58 mL (11.26 mmol) of a solution of 4.37N sodium methanolate in methanol are added and the mixture is stirred at room temperature for two hours before being concentrated under reduced pressure. The residue obtained is taken up in a saturated aqueous solution of sodium chloride and extracted three times with dichloromethane. The combined organic phases are washed once with a saturated aqueous solution of sodium chloride, dried over sodium sulfate, filtered and concentrated to dryness.
  • step 2.3 From 0.19 g (0.61 mmol) of 2- (4'-fluoro-biphenyl-3-yloxy) -7-aza-spiro [3.5] nonane, obtained in step 5.1., Of 0.127 g (0.73 mmol) of methyl 2-hydroxymethyl-thiazole-4-carboxylate, obtained in step 5.2.2, of 0.135 g (0.67 mmol) of para-nitrophenyl chloroformate and 0.265 ml (1, 53 mmol) of N, N-diisopropylethylamine, and after chromatography on silica gel, eluting with a 99/1 mixture of dichloromethane and methanol, 0.161 g of expected product is obtained in the form of a wax.
  • the residue obtained is purified by chromatography on silica gel, eluting with dichloromethane and then with a 99/1 / 0.1 mixture of dichloromethane, methanol and 30% aqueous ammonia.
  • a wax is obtained which crystallizes in diisopropyl ether to give after filtration and drying under vacuum at 60 ° C, 0.087 g of the expected product in the form of a white powder.
  • the medium is stirred for 14 hours at room temperature and then concentrated under vacuum.
  • the residue obtained is taken up with a 1N aqueous sodium hydroxide solution and extracted twice with dichloromethane.
  • the combined organic phases are washed once with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo.
  • the crude residue obtained is taken up in 20 ml of dichloromethane and 10 ml (40 mmol) of a solution of 4N hydrochloric acid in dioxane are added slowly with stirring. After stirring for 3 hours at room temperature, the medium is concentrated under vacuum and the residue is taken up in a 1N aqueous hydrochloric acid solution.
  • the aqueous phase is extracted twice with ethyl acetate and then slowly basified to pH 10 by addition of 35% sodium hydroxide.
  • the aqueous phase is extracted three times with dichloromethane. These three organic extracts are combined, washed once with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo.
  • the expected product is obtained in the form of a wax which is taken up with 2 ml of a solution of 4N hydrochloric acid in dioxane.
  • the medium is diluted with diethyl ether and the precipitate formed is filtered, rinsed with diethyl ether and dried under vacuum.
  • the medium is then heated at 70 ° C. for 14 hours. After returning to ambient temperature, the medium is diluted with a 1N aqueous sodium hydroxide solution and extracted twice with dichloromethane. The combined organic phases are then successively washed twice with 1N aqueous sodium hydroxide solution, once with saturated aqueous ammonium chloride solution and once with saturated aqueous sodium chloride solution. After drying over sodium sulphate, filtration and evaporation to dryness, the residue obtained is purified by chromatography on silica gel, eluting with dichloromethane and then with a 99/1 / 0.1 mixture of dichloromethane, methanol and aqueous ammonia. 30%.
  • the medium, sealed tube is heated to 70 ° C for 14 hours of stirring. After returning to ambient temperature, the medium is diluted with a 1N aqueous sodium hydroxide solution and extracted twice with dichloromethane. The combined organic phases are then successively washed twice with 1N aqueous sodium hydroxide solution, once with saturated aqueous ammonium chloride solution and once with saturated aqueous sodium chloride solution. After drying over sodium sulphate, filtration and evaporation to dryness, the residue is purified by chromatography on silica gel, eluting with a 99/1 / 0.1 and then 98/2 / 0.2 mixture of dichloromethane, methanol and dichloromethane. 30% ammonia.
  • the aqueous phase is extracted a second time with ethyl acetate and the combined organic phases are washed twice with water and once with a saturated aqueous solution of sodium chloride, dried over sulfate. sodium and concentrated to dryness.
  • 1.28 g of the expected isomers 1a and 1b are obtained in the form of an oil.
  • 0.130 g (0.35 mmol) of the mixture of the isomers is separated by chromatography on preparative silica gel plates, eluting with a 70/30 mixture of cyclohexane and ethyl acetate.
  • step 9.2.a From 1.2 g (3.15 mmol) of 2- (toluene-4-sulfonyloxy) -6-aza-spiro [3.4 ] tert-butyl octane-6-carboxylate, isomer 2b., obtained in step 9.1., of 0.622 g (3.30 mmol) of 4'-fluoro-biphenyl-4-ol, of 0.435 g (3, 15 mmol) of potassium carbonate, and 0.831 g (3.15 mmol) of 18-crown-6, and after purification by chromatography on silica gel, eluting with a 90/10 mixture of cyclohexane and acetate of ethyl, 0.860 g of expected product is obtained in the form of a wax used as it is in the next step.
  • step 9.3.a Starting from 0.860 g (2.16 mmol) of tert-butyl 2- (4'-fluoro-biphenyl-4-yloxy) -6-aza-spiro [3.4] octane-6-carboxylate, obtained in step 9.2.b. from the isomer 2b, and 15 mL (60.00 mmol) of a solution of 4N hydrochloric acid in dioxane, 0.545 g of expected product is obtained in the form of a white powder.
  • the medium, sealed tube is heated to 70 ° C for 14 hours of stirring. After returning to ambient temperature, the medium is diluted with a 1N aqueous sodium hydroxide solution and extracted twice with dichloromethane. The combined organic phases are then successively washed twice with 1N aqueous sodium hydroxide solution, once with saturated aqueous ammonium chloride solution and once with saturated aqueous sodium chloride solution. After drying over sodium sulphate, filtration and evaporation under reduced pressure, the residue is purified by chromatography on silica gel, eluting with a 98/2 / 0.2 mixture of dichloromethane, methanol and 30% aqueous ammonia.
  • step 9.4.a From 0.53 g (1.59 mmol) of 2- (4'-fluoro-biphenyl-4-yloxy) hydrochloride. 6-azaspiro [3.4] octane, obtained in step 9.3.b., of 0.561 g (1.75 mmol) of 3-methylcarbamoyl-isoxazol-5-ylmethyl 4-nitro-phenylcarbonate, obtained from step 6.1, 0.83 mL (4.76 mmol) of N, N-diisopropylethylamine and 0.097 g (1.03 mmol) of N, N-dimethylaminopyridine, and after purification by chromatography on silica gel, eluting with a 98/2 / 0.2 mixture of dichloromethane, methanol and aqueous ammonia, 0.638 g of expected product is obtained in the form of a white powder.
  • step 2.1 From 1.50 g (7.03 mmol) of 6-hydroxy-2-aza-spiro [3.3] heptane-2-carboxylate of tert -butyl, obtained in step 10.3., 1.237 g (8.44 mmol) of 4-chloro-3-fluoro-phenol, 1.409 g (8.09 mmol) of diethylazodicarboxylate and 2.121 g (8.09 g).
  • Table 1 which follows illustrates the chemical structures and the physical properties of some compounds according to the invention.
  • the compounds are in free base or salt form.
  • 2 1 1 O H H H HCl 10.
  • Table 2 gives the results of the 1 H NMR analyzes, the melting points (PF), and the M + H masses measured for the compounds of Table 1.
  • Table 3 shows the relative proportions and retention times of the isomers of the compounds 9, 14, 15, 26, 27, 28, 29, 30 and 31, obtained from one of the two methods of chromatographic analysis. below:
  • the compounds of the invention have been the subject of pharmacological tests to determine their inhibitory effect of the enzyme FAAH (Fatty Acid Amide Hydrolase).
  • the inhibitory activity was demonstrated in a radioenzymatic test based on measuring the product of hydrolysis of anandamide [ethanolamine 1- 3 H] by FAAH ( Life Sciences (1995), 56, 1999-2005 and Journal of Biochemical and Biophysical Methods (2004), 60 (2), 171-177 ).
  • mouse brains minus the cerebellum
  • the enzymatic reaction is carried out in 96 well Multiscreen filtration plates in a final volume of 70 ⁇ l.
  • Reaction buffer supplemented with bovine serum albumin without fatty acids (BSA, 1 mg / ml) was used for the enzymatic reaction, the dilution of the compounds and of anandamide [ethanolamine 1- 3 H].
  • BSA bovine serum albumin without fatty acids
  • the reaction is started by addition of anandamide [ethanolamine 1- 3 H] (specific activity 15-20 Ci / mmol) diluted with cold anandamide (10 ⁇ l / well, final concentration of 10 ⁇ M, 0.01 ⁇ Ci per test).
  • anandamide [ethanolamine 1- 3 H] (specific activity 15-20 Ci / mmol) diluted with cold anandamide (10 ⁇ l / well, final concentration of 10 ⁇ M, 0.01 ⁇ Ci per test).
  • the Enzymatic reaction is stopped by addition of a solution of 5M activated carbon prepared in 1.5M NaCl buffer and 0.5M HCl (50 ⁇ l / well). The mixture is stirred for 10 minutes then the aqueous phase containing ethanolamine [ 1-3 H] is recovered by vacuum filtration and counted by liquid scintillation.
  • the inhibitory activity was demonstrated by fluorescent technique in an enzymatic test based on the measurement of the fluorescent hydrolysis product of arachidonoyl 7-amino-4-methyl coumarin amide (AAMC) by FAAH ( Analytical Biochemistry (2005), 343: 143-151 , J. of Biomolecular Screening (2006), 11 (5): 519-527 and J. of Neurosciences Methods (2007), 161: 47-54 ).
  • AAMC arachidonoyl 7-amino-4-methyl coumarin amide
  • the enzymatic reaction is conducted in 384 polystyrene black well plates in a final volume of 50 ⁇ L.
  • Reaction buffer supplemented with bovine serum albumin without fatty acids (BSA, 1 mg / ml) is used for the enzymatic reaction, the dilution of the compounds and the dilution of the AAMC.
  • the most active compounds of the invention have IC 50 (concentration inhibiting by 50% the enzymatic control activity of FAAH) of between 0.001 and 1 ⁇ M.
  • IC 50 concentration inhibiting by 50% the enzymatic control activity of FAAH
  • Compounds Nos. 7, 29, 32 and 33 have IC 50 values of 19 nM, 5.3 nM, 3 nM and 19 nM, respectively.
  • the most active agents of the invention have IC 50 (concentration inhibiting by 50% the enzymatic control activity of FAAH) between 0.001 and 1 ⁇ M.
  • IC 50 concentration inhibiting by 50% the enzymatic control activity of FAAH
  • Compounds Nos. 19 and 25 have IC 50 values of 1.7 nM and 0.46 nM, respectively.
  • the in vivo activity of the compounds of the invention can be evaluated in an analgesia test.
  • intraperitoneal (ip) administration of PBQ phenylbenzoquinone, 2 mg / kg in 0.9% sodium chloride solution containing 5% ethanol
  • PBQ phenylbenzoquinone
  • Test compounds are administered orally (po) or intraperitoneally (ip) in suspension in 0.5% Tween 80, 60 minutes or 120 minutes prior to administration of PBQ.
  • the most potent compounds reduce by 35 to 80% the number of stretching induced by the PBQ, in a range of doses between 1 and 30 mg / kg.
  • compound No. 25 of Table 1 reduces the number of PBQ-induced stretches by 50% at a dose of 30 mg / kg po to 120 minutes.
  • the subject of the invention is also medicaments which comprise a compound of formula (I), or an addition salt with an acid, or a pharmaceutically acceptable hydrate or solvate of the compound of formula (I).
  • These drugs find their use in therapy, especially in the treatment of the above-mentioned pathologies.
  • the present invention relates to pharmaceutical compositions containing, as active ingredient, at least one compound according to the invention.
  • These pharmaceutical compositions contain an effective dose of a compound according to the invention, or an addition salt with an acid, or a hydrate, or a pharmaceutically acceptable solvate of said compound, and optionally one or more pharmaceutically acceptable excipients.
  • Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
  • compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intrathecal, intranasal, transdermal, pulmonary, ocular or rectal administration the active ingredient of formula (I) above, or its salt of addition to an acid, solvate or hydrate if desired, may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prophylaxis or treatment of the above disorders or diseases.
  • Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules, chewing gums and oral solutions or suspensions, sublingual, oral, Intratracheal, intraocular, intranasal, inhalation, subcutaneous, intramuscular or intravenous administration forms and rectal or vaginal administration forms.
  • oral forms such as tablets, soft or hard capsules, powders, granules, chewing gums and oral solutions or suspensions, sublingual, oral, Intratracheal, intraocular, intranasal, inhalation, subcutaneous, intramuscular or intravenous administration forms and rectal or vaginal administration forms.
  • the compounds according to the invention can be used in creams, ointments or lotions.
  • a unitary form of administration of a compound according to the invention in tablet form may comprise the following components: Compound according to the invention 50.0 mg mannitol 223.75 mg Croscaramellose sodium 6.0 mg Corn starch 15.0 mg Hydroxypropylmethylcellulose 2.25 mg Magnesium stearate 3.0 mg
  • Said unit forms are dosed to allow a daily administration of 0.01 to 20 mg of active ingredient per kg of body weight, according to the dosage form.
  • dosages There may be special cases where higher or lower dosages are appropriate, such dosages also belong to the invention.
  • the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.
  • the invention according to another of its aspects, also relates to a method of treatment of the pathologies indicated above which comprises the administration of an effective dose of a compound according to the invention, one of its addition salts with a pharmaceutically acceptable acid, a solvate or a hydrate of said compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (17)

  1. Verbindung mit der Formel (I)
    Figure imgb0088
     worin
    R2 für ein Wasserstoffatom, Fluoratom oder eine Hydroxyl-, Cyano-, Trifluormethyl-, C1-6-Alkyl-, C1-6-Alkoxygruppe, NR8R9 steht;
    m, n, o und p den Wert 1 haben oder p und o den Wert 1 haben, n und m den Wert 2 haben, oder n, o und p den Wert 1 haben und m den Wert 2 hat; A für ein Sauerstoffatom steht;
    R1 für eine Gruppe R5, gegebenenfalls substituiert mit einer oder mehreren Gruppen R6 und/oder R7, steht;
    R5 für eine Gruppe, ausgewählt aus einem Phenyl, Pyridinyl, Pyridazinyl, Pyrimidinyl, Pyrazinyl, Triazinyl, Naphthalinyl, Chinolinyl, Isochinolinyl, Phtalazinyl, Chinazolinyl, Chinoxalinyl, Cinnolinyl, Naphthyridinyl, steht;
    R6 für ein Halogenatom, eine Cyanogruppe, -CH2CN, Nitro, Hydroxyl, C1-6-Alkyl, C1-6-Alkoxy, C1-6-Thioalkyl, C1-6-Haloalkyl, C1-6-Haloalkoxy, C1-6-Halothioalkyl, C3-7-Cycloalkyl, C3-7-Cycloalkyl-C1-3-alkylen, C3-7-Cycloalkyl-C1-3-alkylen-O-, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9 oder -O-(C1-3-Alkylen)-O-steht;
    R7 für eine Gruppe, ausgewählt aus Phenyl, Pyridinyl, Pyridazinyl, Pyrimidinyl, Pyrazinyl, Triazinyl, steht; wobei die Gruppe(n) R7 mit einer oder mehreren Gruppen R6, gleich oder verschieden voneinander, substituiert sein kann/können;
    R3 für ein Wasserstoffatom, Fluoratom, eine C1-6-Alkylgruppe oder eine Trifluormethylgruppe steht;
    R4 für eine Gruppe, ausgewählt aus einem Thiazolyl, einem Triazolyl, einem Oxazolyl und einem Isoxazolyl steht; wobei diese Gruppe nicht substituiert oder mit einer oder mehreren C1-6-Alkylgruppe(n) oder CONR8R9 substituiert ist;
    R8 und R9 unabhängig voneinander für ein Wasserstoffatom oder eine C1-6-Alkylgruppe stehen;
    in Form einer Base oder eines Säureadditionssalzes.
  2. Verbindung mit der Formel (I) nach Anspruch 1, dadurch gekennzeichnet, dass R2 für ein Wasserstoffatom steht,
    in Form einer Base oder eines Säureadditionssalzes.
  3. Verbindung mit der Formel (I) nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass R1 für eine Gruppe R5 steht, die nicht substituiert oder mit einer oder mehreren Gruppen R6 und/oder R7 substituiert ist;
    R5 für eine Phenyl-, Naphthalinyl- oder Isochinolinylgruppe steht;
    R6 für ein Halogenatom, insbesondere ein Fluor- oder Chloratom, oder eine C1-6-Haloalkylgruppe, insbesondere eine Trifluormethylgruppe, oder eine C1-6-Alkoxygruppe, insbesondere eine Ethoxygruppe steht;
    R7 für ein Phenyl steht, das mit einer oder mehreren Gruppen R6, gleich oder verschieden voneinander, substituiert sein kann, in Form einer Base oder eines Säureadditionssalzes.
  4. Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass R3 für ein Wasserstoffatom steht, in Form einer Base oder eines Säureadditionssalzes.
  5. Verbindung mit der Formel (I), ausgewählt aus:
    Thiazol-4-ylmethyl-2-(4-chlorphenoxy)-7-azaspiro[3.5]nonan-7-carboxylat;
    2-Methyl-2H-[1,2,4]triazol-3-ylmethyl-2-(4-chlorphenoxy)-7-aza-spiro[3.5]nonan-7-carboxylat und sein Hydrochlorid;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4-chlorphenoxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4-chlorphenoxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(3-trifluormethylphenoxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(3-trifluormethyl-phenoxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-3-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(7-ethoxynaphthalin-2-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(3-trifluormethylphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat und sein Hydrochlorid (Isomere I + II);
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(3-trifluormethylphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomer I der Verbindung Nr. 9);
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(3-trifluormethylphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomer II der Verbindung Nr. 9);
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-3-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(7-ethoxynaphthalin-2-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    4-Carbamoyl-oxazol-2-ylmethyl-2-(3-trifluormethylphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    4-Methylcarbamoyl-oxazol-2-ylmethyl-2-(3-trifluormethylphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4-chlornaphthalin-1-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4-chlornaphthalin-1-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-4-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-4-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    4-Methylcarbamoyl-thiazol-2-ylmethyl-2-(4'-fluorbiphenyl-3-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(isochinolin-7-yloxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4-chlor-3-fluorphenoxy)-7-aza-spiro[3.5]nonan-7-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-6-(4-chlor-3-fluorphenoxy)-2-aza-spiro[3.3]heptan-2-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-6-(4-chlor-3-fluorphenoxy)-2-aza-spiro[3.3]heptan-2-carboxylat;
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-6-(4'-fluorbiphenyl-4-yloxy)-2-aza-spiro[3.3]heptan-2-carboxylat;
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4-chlor-3-fluorphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4-chlorphenoxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-4-yloxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-4-yloxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Carbamoyl-isoxazol-5-ylmethyl-2-(4-chlornaphthalin-1-yloxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4-chlornaphthalin-1-yloxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomere I + II);
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-4-yloxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomer I der Verbindung 29);
    3-Methylcarbamoyl-isoxazol-5-ylmethyl-2-(4'-fluorbiphenyl-4-yloxy)-6-aza-spiro[3.4]octan-6-carboxylat (Isomer II der Verbindung 29).
  6. Verfahren zur Herstellung einer Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5, umfassend den Schritt des Umsetzens eines Amins mit der allgemeinen Formel (II),
    Figure imgb0089
     worin A, R1, R2, m, n, o und p die in der allgemeinen Formel (I) nach Anspruch 1 definierte Bedeutung haben,
    mit einem Carbonat der allgemeinen Formel (III)
    Figure imgb0090
     worin Z für ein Wasserstoffatom oder eine Nitrogruppe steht, R3 und R4 die in der allgemeinen Formel (I) nach Anspruch 1 definierte Bedeutung haben,
    in Gegenwart einer Base, in einem Lösemittel bei einer Temperatur im Bereich zwischen der Umgebungstemperatur und der Rückflusstemperatur des Lösemittels.
  7. Verfahren zur Herstellung einer Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5, umfassend den Schritt des Umsetzens einer Verbindung mit der allgemeinen Formel (Ia),
    Figure imgb0091
     worin R2, R3, R4, m, n, o und p die in der allgemeinen Formel (I) nach Anspruch 1 definierte Bedeutung haben, und G für einen Teil der Gruppe A steht, wie in der allgemeinen Formel (I) definiert, d. h. eine kovalente Bindung;
    entweder mit einem Alkoholderivat mit der allgemeinen Formel R1OH (IV), worin R1 die in der allgemeinen Formel (I) nach Anspruch 1 definierte Bedeutung hat, unter Verwendung der Bedingungen der Mitsunobu-Reaktion;
    oder mit einem Halogenderivat mit der allgemeinen Formel R1X (IVa), worin R1 die in der allgemeinen Formel (I) nach Anspruch 1 definierte Bedeutung hat, und X für ein Fluor-, Chlor-, Brom - oder Iodatom steht, unter Verwendung der Buchwald-Reaktionen zur nukleophilen aromatischen, heteroaromatischen Substitution oder O-Arylierung, O-Heteroarylierung.
  8. Verfahren zur Herstellung einer Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5, worin R1 für eine Gruppe R5 steht, die insbesondere mit einer Gruppe R6 vom Typ C1-6-Alkyl, C3-7-Cycloalkyl oder C3-7-Cycloalkyl-C1-3-alkylen, oder mit einer Gruppe R7, wie in der allgemeinen Formel (I) nach Anspruch 1 definiert, substituiert ist, umfassend den Schritt der Durchführung einer Kopplungsreaktion, die mithilfe eines Übergangsmetalls katalysiert wird, an der Verbindung mit der allgemeinen Formel (Ib),
    Figure imgb0092
     worin A, R2, R3, R4, R5, m, n, o und p sind, wie in der allgemeinen Formel (I) nach Anspruch 1 definiert, und U1 für ein Chlor-, Brom-, Iodatom oder eine Triflat-Gruppe steht, wobei U1 in der Position steht, an der die Gruppe R6 oder R7 eingeführt werden soll:
    - oder durch eine Reaktion vom Typ Suzuki, zum Beispiel mithilfe einer Alkyl-, Cycloalkyl-, Aryl- oder Heteroarylboronsäure,
    - oder gemäß einer Reaktion vom Typ Stille, zum Beispiel unter Verwendung eines Aryl- oder Heteroaryl-tri-Zinntetraalkylderivats,
    - oder durch eine Reaktion vom Typ Negishi, zum Beispiel unter Verwendung eines Alkyl-, Cycloalkyl-, Aryl- oder Heteroarylhalogenidzinkatderivats,
  9. Verbindung mit der Formel (III):
    Figure imgb0093
     worin Z für ein Wasserstoffatom oder eine Nitrogruppe steht, R3 die in der Formel (I) definierte Bedeutung hat, und R4 für eine 3-(Methylcarbamoyl)-isoxazol-5-ylmethylgruppe steht.
  10. Verbindung mit der allgemeinen Formel (Ia) :
    Figure imgb0094
     worin R2, R3, R4, m, n, o und p die in Anspruch 1 definierte Bedeutung haben, und G für einen Teil der Gruppe A steht, wie in der allgemeinen Formel (I) definiert, d. h. eine kovalente Bindung.
  11. Verbindung mit der allgemeinen Formel (IIa):
    Figure imgb0095
     worin R2 die in der allgemeinen Formel (I) von Anspruch 1 definierte Bedeutung hat, o und p für 1 stehen, m und n für 1 oder 2 stehen, aber m und n zusammen nicht für den Wert 2 stehen, G für einen Teil der Gruppe A steht, wie in der allgemeinen Formel (I) definiert, nämlich eine kovalente Bindung, und GP für eine Schutzgruppe, wie z. B. Boc (tert-Butyoxyocarbonyl), Cbz (Benzyloxycarbonyl, Benzyl oder Benzhydryl, steht.
  12. Verbindung mit der allgemeinen Formel (II):
    Figure imgb0096
     worin R1, R2, m, n, o und p die in Anspruch 1 definierte Bedeutung haben, A für ein Sauerstoffatom steht, wenn R1 keine Fluorphenylgruppe ist.
  13. Verbindung mit der allgemeinen Formel (IIe):
    Figure imgb0097
     worin R2 die in Anspruch 1 definierte Bedeutung hat, o und p für 1 stehen, m und n für 1 oder 2 stehen, aber m und n zusammen nicht für den Wert 2 stehen, G für einen Teil der Gruppe A steht, wie in der allgemeinen Formel (I) definiert, d. h. eine kovalente Bindung, und GP für eine Schutzgruppe, wie z. B. Boc (tert-Butyoxyocarbonyl), Cbz (Benzyloxycarbonyl, Benzyl oder Benzhydryl, steht.
  14. Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5 in Form einer Base oder eines Additionssalzes einer pharmazeutisch verträglichen Säure zur Verwendung als Medikament.
  15. Pharmazeutische Zusammensetzung, enthaltend mindestens eine Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5 in Form einer Base oder eines Additionssalzes einer pharmazeutisch verträglichen Säure und gegebenenfalls einem oder mehreren pharmazeutisch verträglichen Exzipienten.
  16. Verwendung einer Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5 in Form einer Base oder eines Additionssalzes einer pharmazeutisch verträglichen Säure zur Herstellung eines Medikaments, das dazu bestimmt ist, eine Erkrankung zu verhindern oder zu behandeln, an der die endogenen Cannabinoide und/oder alle anderen Substrate, die durch das Enzym FAAH verstoffwechselt werden, beteiligt sind.
  17. Verwendung einer Verbindung mit der Formel (I) nach einem der Ansprüche 1 bis 5 in Form einer Base oder eines Additionssalzes einer pharmazeutisch verträglichen Säure zur Herstellung eines Medikaments, das dazu bestimmt ist, chronische oder akute neurogene Schmerzen, akute oder chronische Schmerzen, die mit Entzündungskrankheiten verbunden sind, akute oder chronische periphere Schmerzen, Schwindelzustände, Erbrechen, Übelkeiten, Störungen des Essverhaltens, neurologische und psychiatrische Erkrankungen, akute oder chronische neurodegenerative Krankheiten, Epilepsie, Schlafstörungen, Herz-Kreislauf-Krankheiten, Nierenischämie, Krebsformen, Störungen des Immunsystems, allergische Krankheiten, parasitäre, virale oder bakterielle Infektionskrankheiten, Entzündungskrankheiten, Osteoporose, Augenleiden, Lungenleiden, Magen-Darm-Krankheiten, Harninkontinenz oder Blasenentzündung zu verhindern oder zu behandeln.
EP10728742.7A 2009-05-12 2010-05-11 7-aza-spiro[3,5]nonan-7-carboxylatderivate, deren herstellung und deren therapeutische verwendung Active EP2430012B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902269A FR2945531A1 (fr) 2009-05-12 2009-05-12 Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
PCT/FR2010/050914 WO2010130945A1 (fr) 2009-05-12 2010-05-11 Dérivés de 7-aza-spiro[3.5]nonane-7-carboxylates, leur prépraration et leur application en thérapeutique

Publications (2)

Publication Number Publication Date
EP2430012A1 EP2430012A1 (de) 2012-03-21
EP2430012B1 true EP2430012B1 (de) 2014-11-05

Family

ID=41258889

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10728742.7A Active EP2430012B1 (de) 2009-05-12 2010-05-11 7-aza-spiro[3,5]nonan-7-carboxylatderivate, deren herstellung und deren therapeutische verwendung

Country Status (21)

Country Link
US (2) US8394787B2 (de)
EP (1) EP2430012B1 (de)
JP (1) JP5680624B2 (de)
KR (1) KR20120015454A (de)
CN (1) CN102459232B (de)
AR (1) AR076563A1 (de)
AU (1) AU2010247214B2 (de)
BR (1) BRPI1013932A2 (de)
CA (1) CA2761663C (de)
CL (1) CL2011002835A1 (de)
CO (1) CO6460743A2 (de)
EA (1) EA201171387A1 (de)
FR (1) FR2945531A1 (de)
IL (1) IL216238A0 (de)
MA (1) MA33354B1 (de)
MX (1) MX2011012061A (de)
SG (1) SG176042A1 (de)
TN (1) TN2011000570A1 (de)
TW (1) TW201043619A (de)
UY (1) UY32630A (de)
WO (1) WO2010130945A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
AR079934A1 (es) * 2010-01-20 2012-02-29 Sanofi Aventis Derivados de carbamato de alquil -heterociclos, su preparacion y su aplicacion en terapeutica
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
DK2780015T3 (en) 2011-11-18 2017-03-27 Heptares Therapeutics Ltd M1 MUSCARINRECEPTORAGONISTER
US9822129B2 (en) 2012-03-02 2017-11-21 Genentech, Inc. Amido spirocyclic amide and sulfonamide derivatives
EP3102568B1 (de) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclische azaverbindungen als agonisten des muscarinischen m1-rezeptors und/oder m4-rezeptors
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201702225A (zh) * 2015-05-14 2017-01-16 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途
GEP20207105B (en) 2015-07-31 2020-05-11 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
EP3571191A1 (de) * 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamatderivate als magl-inhibitoren
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
EA201991898A1 (ru) * 2017-03-13 2020-02-07 Эбайд Терапьютикс, Инк. Двойные ингибиторы magl и faah
CA3079188A1 (en) * 2017-10-17 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP3732163A4 (de) 2017-12-20 2021-07-14 Vanderbilt University Antagonisten des muskarinischen acetylcholinrezeptors m4
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678335B2 (ja) 1991-06-19 1994-10-05 ファイザー・インコーポレーテッド アザスピロキノロン化合物、その製法および抗菌組成物
WO1998006720A1 (fr) 1996-08-09 1998-02-19 Eisai Co., Ltd. Derives de benzopiperidine
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) * 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
CA2571058A1 (en) * 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
WO2006006490A1 (ja) * 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
JP2008546828A (ja) * 2005-06-28 2008-12-25 ノイロサーチ アクティーゼルスカブ 新規な３−アザ−スピロ［５．５］ウンデカン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのこれらの使用
CA2658545A1 (en) 2006-07-24 2008-01-31 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
EP2217596B8 (de) * 2007-10-22 2013-11-20 Merck Sharp & Dohme Corp. Bicyclische heterocyclische derivate und ihre verwendung als modulatoren der aktivität von gpr 119

Also Published As

Publication number Publication date
TW201043619A (en) 2010-12-16
EP2430012A1 (de) 2012-03-21
CA2761663C (fr) 2017-04-18
SG176042A1 (en) 2011-12-29
CL2011002835A1 (es) 2012-06-22
WO2010130945A1 (fr) 2010-11-18
AR076563A1 (es) 2011-06-22
KR20120015454A (ko) 2012-02-21
US8394787B2 (en) 2013-03-12
JP2012526784A (ja) 2012-11-01
BRPI1013932A2 (pt) 2018-02-27
US20120129830A1 (en) 2012-05-24
AU2010247214B2 (en) 2015-07-02
IL216238A0 (en) 2012-01-31
CA2761663A1 (fr) 2010-11-18
MA33354B1 (fr) 2012-06-01
FR2945531A1 (fr) 2010-11-19
AU2010247214A1 (en) 2011-12-08
UY32630A (es) 2010-12-31
CO6460743A2 (es) 2012-06-15
JP5680624B2 (ja) 2015-03-04
EA201171387A1 (ru) 2012-05-30
TN2011000570A1 (fr) 2013-05-24
CN102459232B (zh) 2014-05-07
MX2011012061A (es) 2012-02-28
CN102459232A (zh) 2012-05-16
US20130211087A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
EP2430012B1 (de) 7-aza-spiro[3,5]nonan-7-carboxylatderivate, deren herstellung und deren therapeutische verwendung
EP2430006B1 (de) Cyclopenta[c]pyrrol-2-carboxylat-derivate, ihre zubereitung und therapeutische verwendung
EP2393809B1 (de) Derivate von azaspiranylalkylcarbamaten 5-gliedriger heterocyclischer verbindungen, deren herstellung und deren therapeutische verwendung
EP2344486B1 (de) Alkylthiazolcarbamat-verbindungen, deren herstellungsverfahren und verwendung als faah hemmer
EP1720872B1 (de) Aryl- und heteroarylpiperidincarboxylatderivate, deren herstellung und deren verwendung in form von faah-enzyminhibitoren
EP1537096B1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
EP1879856B1 (de) Alkyl-, alkenyl- und alkynylcarbamat-derivate, deren herstellung und therapeutische verwendung
EP2429998B1 (de) Cyclopenta[c]pyrrolylalkylcarbamat-derivate aus einer 5-gliedrigen heterocyclischen verbindung, ihre herstellung und therapeutische verwendung
EP1720848B1 (de) Derivate von alkylpiperazin- und alkylhomopiperazincarboxylaten, verfahren zu deren herstellung und deren verwendung als inhibitoren des faah-enzyms
WO2004099176A1 (fr) Derives de piperidinyl- et piperazinyl-alkylcarbamates, leurs procedes de preparation et leur application en therapeutique
EP1708994B1 (de) Derivate vom aryloxyalkylcarbamat-typ, verfahren zu deren herstellung und deren verwendung in therapeutika
EP2356108B1 (de) Carbamatderivate von alkylheterocyclen, deren herstellung und deren therapeutische verwendung
EP1720550B1 (de) Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
EP1720829A1 (de) Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren
FR2955325A1 (fr) Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167146

Country of ref document: HK

17Q First examination report despatched

Effective date: 20130517

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140624

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 694559

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010019966

Country of ref document: DE

Effective date: 20141218

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 694559

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141105

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20141105

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150305

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150205

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150305

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150206

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010019966

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141105

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1167146

Country of ref document: HK

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240321

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240308

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240319

Year of fee payment: 15